Content about Jordan

December 28, 2012
Teva delays sales of Gilead generics pending court ruling

Teva Pharmaceuticals USA will delay the sales of generic versions of two Gilead Sciences HIV drugs until June 2013, the company stated.

January 18, 2012
Gilead completes acquisition of Pharmasset

Drug maker Gilead Sciences has completed its $11.2 billion acquisition of Pharmasset, Gilead said.

November 21, 2011
Gilead Sciences acquires Pharmasset for $11 billion

Drug maker Gilead Sciences will acquire Pharmasset for $11 billion, or $137 per share, Gilead said Monday.

October 6, 2011
Gilead, Boehringer Ingelheim ink license agreement

Gilead Sciences has signed an agreement with Boehringer Ingelheim to gain exclusive worldwide rights to research, develop and commercialize BI's novel anti-retroviral compounds.

July 19, 2011
Matrix expands licensing agreement with Gilead for HIV/AIDS therapies

Mylan subsidiary Matrix Labs has expanded its licensing agreement with Gilead Sciences.

July 19, 2011
Ranbaxy to produce, market antiretrovirals under licensing agreement with Gilead

Ranbaxy will produce and market three HIV/AIDS drugs that currently are in late-stage clinical development by Gilead under a new licensing agreement between the drug makers.

June 28, 2011
Gilead, Tibotec to develop HIV drug

A subsidiary of Johnson & Johnson and Gilead Sciences will collaborate to develop a combination drug for HIV, the two companies said Tuesday.

March 17, 2011
Gilead, Roche sue Natco Pharma over generic Tamiflu

Drug makers Gilead Sciences and Roche are suing Indian drug maker Natco Pharma concerning a generic version of an influenza treatment, according to published reports.

March 14, 2011
Gilead to shareholders: Say no to mini-tender offer by TRC

Drug maker Gilead acknowledged the receipt of an unsolicited mini-tender offer by TRC Capital.

March 4, 2011
FDA lifts liver injury risk boxed warning from Gilead's Letairis

Gilead on Friday announced that the Food and Drug Administration has removed a boxed warning about a possible liver injury risk caused by the drug maker's hypertension treatment.

June 27, 2010
Gilead to acquire CGI

Gilead Sciences plans to acquire a development-stage pharmaceutical company for up to $120 million, Gilead...

© 2013 Drug Store News. All Rights Reserved.